Awareness of physicians in Jordan about the treatment of high blood pressure according to the seventh report of the Joint National Committee (JNC VII)

European Journal of Cardiovascular Nursing

Volumn 6, Issue 3, 2007, Pages 223-232

  Al Azzam, Sayer Ibrahim ^a   Najjar, Rula Basem ^a   Khader, Yousef Saleh ^b  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^b Family Medicine   (Jordan)

Author keywords

Awareness; Hypertension; JNC VII; Jordan; Physicians

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; LABETALOL; NIFEDIPINE; NITROPRUSSIDE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; AWARENESS; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; HEALTH CARE ORGANIZATION; HUMAN; HYPERTENSION; JORDAN; MEDICAL PRACTICE; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; QUESTIONNAIRE;

ADULT; AGE FACTORS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ATTITUDE OF HEALTH PERSONNEL; AWARENESS; CLINICAL COMPETENCE; CURRICULUM; EDUCATION, MEDICAL, CONTINUING; EDUCATIONAL MEASUREMENT; GUIDELINE ADHERENCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; HYPERTENSION; INTERNSHIP AND RESIDENCY; JORDAN; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PRACTICE GUIDELINES; QUESTIONNAIRES; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 34547809333     PISSN: 14745151     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcnurse.2006.10.001     Document Type: Article

References (31)

1. Hajjar I., and Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290 (2003) 199-206
2. Jaddou H.Y., Bateiha A.M., Al-Khateeb M.S., and Ajlouni K.M. Epidemiology and management of hypertension among Bedouins in Northern Jordan. Saudi Med J 5 (2003) 472-476
3. Khasawneh N.F., Al-Safi S., Albsoul-Younes A., and Borqan O.N. Clustering of coronary artery disease risk factors in Jordanian hypertensive patients. Saudi Med J 26 (2005) 215-219
4. Jaddou H.Y., Batiehah A.M., and Ajlouni K.M. Prevalence and associated factors of hypertension: results from a three community-based survey, Jordan. J Hum Hypertens 10 (1996) 815-821
5. Hammoudeh AJ, Al-Tarawneh H, Elharassis A, Haddad J, Mahadeen Z, Badran N, Izraiq M, Al-Mousa E, in press. Prevalence of conventional risk factors in Jordanians with coronary heart disease: The Jordan Hyperlipidemia and Related Targets Study (JoHARTS). Int J Cardiol 2005 Oct 16.
6. Hemmelgarn B.R., Grover S., and Feldman R.D. Canadian Hypertension Education Program. Applying the 2005 Canadian Hypertension Education Program recommendations: 2. Assessing and reducing global atherosclerotic risk among hypertensive patients. CMAJ 173 (2005) 593-595
7. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289 (2003) 2560-2571
8. Liszka H.A., Mainous III A.G., King D.E., Everett C.J., and Egan B.M. Prehypertension and cardiovascular morbidity. Ann Fam Med 3 (2005) 294-299
9. Ajlouni K., Jaddou H., and Batieha A. Diabetes and impaired glucose tolerance in Jordan: prevalence and associated risk factors. J Intern Med 244 (1998) 317-323
10. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
11. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic versus β-blocker as first-step antihypertensive therapy final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Hypertension 42 (2003) 239-246
12. Vidt D.G. Diuretics are still the preferred initial drugs for high blood pressure. Clevel Clin J Med 70 (March 2003) 263-269
13. Lauer M.S. Aspirin for primary prevention of coronary events. N Engl J Med 346 (2002) 1468-1474
14. Saloheimo P., Juvela S., and Hillbom M. Use of aspirin, epistaxis, and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people. Stroke 32 (2001) 399-404
15. Remme W.J. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN)- rationale and Design. Cardiovasc Drugs Ther 15 (2001) 69-77
16. Abraira C., Duckworth W., McCarren M., Emanuele N., Arca D., Reda D., et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2 Veterans Affairs Diabetes Trial. J Diabetes Its Complicat 17 (2003) 314-322
17. McCarty M.F. ACE inhibition may decrease diabetes risk by boosting the impact of bradykinin on adipocytes. Med Hypotheses 60 (2003) 779-783
18. Himmelmann A. New information on the role of beta-blockers in cardiac therapy. Cardiovasc Drugs Ther 13 (1999) 469-477
19. 2005 Canadian recommendations for the management of hypertension.
20. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., and for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
21. Fonarow G.C. An approach to heart failure and diabetes mellitus. Am J Cardiol 96 (2005) 47E-52E [suppl]
22. Strippoli G.F.M., Craig M., Deeks J.J., Schena F.P., and Craig J.C. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 329 (2004) 828-831
23. Contreras G., Greene T., Agodoa L.Y., Cheek D., Junco G., Dowie D., et al. Blood pressure control, drug therapy, and kidney disease. Hypertension 46 (2005) 44-50
24. Giatras I., Lau J., and Levey A.S. Effect of angiotensin-converting enzyme inhibitors on the progresssion of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 127 (1997) 337-345
25. Maschio G., Alberti D., Janin G., Locatelli F., Mann J.F., Motolese M., et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Insufficiency Study Group. N Engl J Med 334 (1996) 939-945
26. GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline of glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349 (1997) 1857-1863
27. Ruggenenti P., Perna A., Gherardi G., Gaspari F., Benini R., and Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy on long term ramipril: REIN follow-up trial. Lancet 352 (1998) 1252-1256
28. Harrow C.J., and Fisher M. Strokes and diabetes. Pract Diabetes Int 22 (2005) 215-221
29. PROGRESS Collaborative Group:, Tzourio C., Anderson C., Chapman N., Woodward M., Neal B., MacMahon S., et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163 (2003) 1069-1075
30. Johnson B.A., Ait-Daoud N., and Wells L.T. Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on d-methamphetamine-induced cognitive and physiological changes in humans. Neuropsychopharmacology 22 (2000) 504-512
31. Evans C.E., Haynes R.B., Gilbert J.R., Taylor D.W., Sackett D.L., and Johnston M. Educational package on hypertension for primary care physicians. Can Med Assoc J 130 (1984) 719-722